

PRESS RELEASE

Laboratoire X.O

Paris, Octobre 29th 2021 – Laboratoire X.O closed a transaction with Astellas Pharma Inc. regarding the Nicardipine rights (3 brands) in 4 countries in Europe . This will strengthen our portfolio of 24 brands as well as our European footprint. Since its creation in 2015 , Laboratoire X.O has completed 12 M&A operations and confirmed its position of reliable partner with Big Pharma. in case of portfolio divestiture.

The transaction includes product registrations, intellectual property, certain contracts and inventory. The deal does not include any transfer of manufacturing facilities or employees.

About Astellas Pharma Inc

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world.

They are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality.

Furthermore, they are also looking beyond their foundational Rx focus to create Rx+® healthcare solutions that combine their expertise and knowledge with cutting-edge technology in different fields of external partners.

Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

For more information, please visit the website at <https://www.astellas.com/en>

About Laboratoire X.O

Dynamic French pharmaceutical company on a human scale, Laboratoire X.O is a pharmaceutical company with mature marketing authorisations in various therapeutic areas such as pain, central nervous system, cardiology, oral health and women's health.

They have grown both organically through the success of their brands, through international expansion and through external growth, including more than 12 acquisitions in the last 5 years.

Laboratoire XO is committed to being as close as possible to the needs of healthcare professionals and patients, whether through their medicines, medical devices or cosmetic products.

They rely on their own network of medical sales representatives as well as partner networks of pharmaceutical representatives, ready to invest in the development of their products.

For more information, please visit the website at <https://laboratoirexo.fr/>

Contacts

Antoine WISNIEWSKI (France)

Laboratoire X.O

antoinewisniewski@laboratoirexo.fr